- Home
- Media Center
- Press releases
- Medical technologies
Medical technologies
Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE™ Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation
The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy1 Approval is supported by the admIRE study, where 85% peak primary effectiveness 12-month success and minimal-to-no fluoroscopy were achieved2,i
Shockwave Medical Further Validates Utility of Intravascular Lithotripsy in Lower Limb Lesions in Late-Breaking Presentation at VIVA 2024
DISRUPT BTK II, a global post-market study, finds favorable 30-day outcomes for peripheral IVL in the most challenging calcified lesions, including patients with CLTI
Johnson & Johnson MedTech Completes Pilot Phase Enrollment of OMNY-AF Trial Evaluating Large-Tip, Focal Pulsed Field Ablation OMNYPULSE™ Catheter
The OMNY-AF trial evaluates safety and efficacy of the investigational OMNYPULSE™ Platform, a novel catheter that combines a large ablation area with mapping capabilities
Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
The first prospective female-only study of coronary interventions in complex calcific disease, EMPOWER CAD aims to confirm benefits of Shockwave intravascular lithotripsy in women Co-Principal Investigator Margaret McEntegart, MD, completed enrollment during a live case at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C.
New Data at TCT 2024 Expands on Recently Published New England Journal of Medicine Randomized Controlled Trial Demonstrating a Survival Benefit from Impella® Heart Pumps
Also at TCT: Impella ECP Pivotal Study Presentation
Johnson & Johnson MedTech Launches VOLT™ Plating System
Next-Generation Plating System combines flexibility and stability for advanced fracture care1-4* across orthopaedic procedures5,6
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3†. 93% of patients become free from glasses at all distances. #4‡ TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶
Shockwave Medical Expands U.S. Peripheral IVL Portfolio with Enhanced Catheter
Shockwave E8 Augments IVL’s Capabilities for Physicians Treating Peripheral Arterial Disease Above and Below the Knee